

GENTA INC DE/  
Form 8-K  
November 09, 2004

---

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**  
**WASHINGTON, D.C. 20549**

---

**FORM 8-K**

**CURRENT REPORT PURSUANT  
TO SECTION 13 OR 15(d) OF THE  
SECURITIES EXCHANGE ACT OF 1934**

Date of report (Date of earliest event reported): November 8, 2004

**GENTA INCORPORATED**

(Exact Name of Registrant as Specified in Its Charter)

**Delaware**

(State or Other Jurisdiction of Incorporation)

**0-19635**  
(Commission File Number)

**33-0326866**  
(IRS Employer Identification No.)

**Two Connell Drive**  
**Berkeley Heights, NJ**  
(Address of Principal Executive Offices)

**07922**  
(Zip Code)

**(908) 286-9800**  
(Registrant's Telephone Number, Including Area Code)

(Former Name or Former Address, if Changed Since Last Report)

---

**Item 1.02 Termination of a Material Definitive Agreement.**

On November 8, 2004, Genta Incorporated ( Genta ) issued a press release announcing that the Company has received from Aventis notice of termination of the agreements between Genta and Aventis, part of the sanofi-aventis Group, regarding the development and commercialization of Genasense® (oblimersen sodium) Injection. The press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.

**Item 2.02 Results of Operations and Financial Condition.**

On November 9, 2004, Genta issued a press release reporting the results of its operations for the three months ended September 30, 2004. The press release is attached hereto as Exhibit 99.2 and incorporated herein by reference.

**Item 8.01 Other Events.**

On November 8, 2004, Genta issued a press release announcing results of the Company's randomized Phase 3 clinical trial of Genasense® (oblimersen sodium) Injection in patients with relapsed or refractory chronic lymphocytic leukemia (CLL). The press release is attached hereto as Exhibit 99.3 and incorporated herein by reference.

<u>Exhibit Number</u>	<u>Description</u>
99.1	Press Release dated November 8, 2004
99.2	Press Release dated November 9, 2004
99.3	Press Release dated November 8, 2004

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

GENTA INCORPORATED

Date: November 9, 2004

By: /s/ William P. Keane

Name: William P. Keane

Title: Vice President, Chief Financial  
Officer and Corporate Secretary

---

**EXHIBIT INDEX**

<b>Exhibit Number</b>	<b>Description</b>	<b>Sequentially Numbered Page</b>
99.1	Press Release dated November 8, 2004	
99.2	Press Release dated November 9, 2004	
99.3	Press Release dated November 8, 2004	

---